1. Home
  2. ACOG vs QNCX Comparison

ACOG vs QNCX Comparison

Compare ACOG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.86

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$29.44

Market Cap

17.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
QNCX
Founded
2000
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.6M
17.5M
IPO Year
2024
2019

Fundamental Metrics

Financial Performance
Metric
ACOG
QNCX
Price
$8.86
$29.44
Analyst Decision
Strong Buy
Hold
Analyst Count
2
2
Target Price
$16.00
N/A
AVG Volume (30 Days)
162.7K
17.2K
Earning Date
05-14-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
41.58
N/A
EPS
N/A
N/A
Revenue
$10,220,275.00
N/A
Revenue This Year
$139.22
N/A
Revenue Next Year
$134.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.50
$0.08
52 Week High
$10.14
$35.41

Technical Indicators

Market Signals
Indicator
ACOG
QNCX
Relative Strength Index (RSI) 47.57 46.63
Support Level $5.28 $0.82
Resistance Level $9.04 $35.38
Average True Range (ATR) 0.55 2.07
MACD -0.09 -1.04
Stochastic Oscillator 3.91 4.41

Price Performance

Historical Comparison
ACOG
QNCX

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Share on Social Networks: